BiotechTube
Home/reMYND/Nancy Van Osselaer, PhD
NV

Nancy Van Osselaer, PhD

Development Advisor

reMYND

Therapeutic Areas

Alzheimer's DiseaseHuntington's DiseaseAmyotrophic Lateral Sclerosis (ALS)

reMYND Pipeline

DrugIndicationPhase
REM392 (Alzheimer's Program)Alzheimer's DiseasePre-clinical
Huntington's ProgramHuntington's DiseasePre-clinical
Discovery ProgramAmyotrophic Lateral Sclerosis (ALS)Discovery

Leadership Team at reMYND

FS
Floor Stam, PhD
CEO
GG
Gerard Griffioen, PhD
CSO
CF
Chris Freitag, MD
Clinical Advisor
KP
Katrien Princen, PhD
Head of Operations
SL
Sara Lambrechts
Head of Finance
View full reMYND profile